Assembly Biosciences, Inc. (ASMB) Stock Grade

About Assembly Biosciences, Inc.'s fundamentals

Assembly Biosciences is a biotechnology company with a market capitalization of $467.9 million that is experiencing significant revenue expansion, with year-over-year growth of 153.5%, though it currently operates at a net loss with a negative net margin of -8.5%. The company trades at a P/E ratio of 75.9, reflecting investor expectations for future profitability, and does not currently pay dividends. As a loss-making biotech firm in early-stage growth, Assembly Biosciences is typical of companies prioritizing revenue development and product advancement over near-term profitability.